Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Zenotech Laboratories's 10-Year RORE % for the quarter that ended in Jun. 2026 was 285.87%.
The industry rank for Zenotech Laboratories's 10-Year RORE % or its related term are showing as below:
BOM:532039's 10-Year RORE % is ranked better than 98.95% of 669
companies
in the Drug Manufacturers industry
Industry Median: 6.33
vs BOM:532039: 285.87
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Zenotech Laboratories 10-Year RORE % Related Terms
Zenotech Laboratories 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Zenotech Laboratories's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenotech Laboratories 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Zenotech Laboratories's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 10-year before.
Zenotech Laboratories (BOM:532039) has a 10-Year RORE % of 285.87 as of Jun. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Zenotech Laboratories and its competitors. According to the industry distribution chart, Zenotech Laboratories ranks #7 out of 669 companies in the Drug Manufacturers industry, placing it in the top 1%.
Is Zenotech Laboratories' 10-Year RORE % too high?
Zenotech Laboratories' current 10-Year RORE % is 285.87. The Drug Manufacturers industry median 10-Year RORE % is 6.33. Zenotech Laboratories' value of 285.87 is 4416.1% above this industry median. Based on the distribution chart, Zenotech Laboratories ranks #7 out of 669 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zenotech Laboratories has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenotech Laboratories' 10-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenotech Laboratories ranks #7 out of 669 companies for 10-Year RORE %. This places Zenotech Laboratories in the top 1% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 6.33. Zenotech Laboratories' value of 285.87 is 4416.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.33, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenotech Laboratories's current 10-Year RORE % of 285.87 is 4416.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Zenotech Laboratories and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenotech Laboratories's current 10-Year RORE % is 285.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenotech Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zenotech Laboratories (BOM:532039) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹64.68, compared to a current price of ₹44.98 — trading 30.5% below its estimated fair value. The current 10-Year RORE % is 285.87 and 4416.1% above the Drug Manufacturers industry median of 6.33. Zenotech Laboratories' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Zenotech Laboratories (BOM:532039), the current 10-Year RORE % is 285.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenotech Laboratories (BOM:532039) Overvalued in 2026?
Based on GuruFocus' analysis, Zenotech Laboratories stock appears to be undervalued.
The current stock price of ₹44.98 is trading 30.5% below its estimated GF Value™ of ₹64.68.
GuruFocus considers Zenotech Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:532039:
10-Year RORE %: 285.87
GF Value™: ₹64.68 vs. price of ₹44.98 (30.5% below fair value)
Industry Position: 4416.1% above the Drug Manufacturers median (#7 of 669)
No single metric tells the full story. See the BOM:532039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
68GF Score
Get the complete analysis for BOM:532039
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532039 has been successfully added to your 
